Method of increasing the relative number of CD45 low cells in a cell population

• US 7,112,440 B2
• Filed: 12/20/2000
• Issued: 09/26/2006
• Est. Priority Date: 02/02/1995
• Status: Expired due to Term

• Current Assignee: Ghazi Jaswinder Dhoot
• Original Assignee: Ghazi Jaswinder Dhoot
• Inventors: Abuljadayel, Ilham
• Primary Examiner(s): SAUNDERS, DAVID A
• Application Number:
  US09/742,520
• Publication Number:
  US 20010024826A1
• Time in Patent Office: 2,106 Days
• Field of Search: 435/7.1, 435 721- 724, 435/34, 435/372, 435/372.2, 435/377, 436/501
• US Class Current: 435/372
• CPC Class Codes: C12N 2501/06 Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
• CPC Class Codes: C12N 2501/50 Cell markers; Cell surface determinants
• CPC Class Codes: C12N 2506/11 from blood or immune system cells
• CPC Class Codes: C12N 5/0634 Cells from the blood or the immune system

Abstract

A method of increasing the relative number of CD45 low cells in a cell population is described. The method comprises contacting a more committed cell with an agent that causes the more committed cell to retrodifferentiate into an undifferentiated cell, which undifferentiated cell is a CD45 low cell.

Claims

1. A method of increasing the relative number of CD45 low cells in an untreated starting cell population, wherein the starting cell population comprises a CD45 low cell sub-population and a CD45 high sub-population, and wherein the cells of the CD45 low sub-population have a lower relative density of CD45 antigen on their cell surface as compared to the cells of the CD45 high sub-population, and wherein the starting cell population includes committed hemopoietic cells comprising CD45 antigen, which method comprises:

(i) determining that the starting cell population comprises a CD45 low cell sub-population and a CD45 high sub-population

(ii) contacting the starting cell population with an agent selected from the group consisting of an antibody to the alpha chain of the MHC class I antigen, an antibody to the beta chain of the MHC class I antigen, an antibody to the alpha chain of the MHC class II antigen, and an antibody to the beta chain of the MHC class II antigen and

(iii) incubating the starting cell population with the agent,

whereby as a result of the contacting, a treated cell population is produced, in which the number of CD45 low cells is increased relative to the number of CD45 high cells.

2. The method according to claim 1 wherein said incubating is from 2 to 24 hours.

3. The method according to claim 1 wherein the committed hemopoietic cells are non-cancer cells.

4. The method according to claim 1 wherein the committed hemopoietic cells are differentiated cells.

5. The method according to claim 1, wherein the committed hemopoietic cells are human leukocytes, wherein the human leukocytes are found in peripheral blood, thymus spleen or tonsil tissue, and wherein the leukocytes are selected from the group consisting of lymphocytes, monocytes, polymorphonuclear cells, eosinophils and basophills.

6. A method according to claim 1 wherein said MHC class I antigen is a Human-Leukocyte-Associated (HLA)-A receptor, an HLA-B receptor, an HLA-C receptor, an HLA-E receptor, an HLA-F receptor or an HLA-G receptor and said class II antigen is an HLA-DM receptor, an HLA-DP receptor, an HLA-DQ receptor or an HLA-DR receptor.

7. The method according to claim 6 wherein the MHC class II antigen is an HLA-DR receptor.

8. A method according to claim 1 wherein the agent is a monoclonal antibody.

9. A method according to claim 8 wherein the antibody is selected from the group consisting of monoclonal antibody CR3/43 and monoclonal antibody TAL 1B5.

10. A method according to claim 1 wherein the agent is used in conjunction with an alkylating agent.

11. A method according to claim 10 wherein the alkylating agent is or comprises cyclophosphoamide.

12. The method according to claim 1, wherein the committed hemopoietic cells are leukocyte progenitors found in bone marrow.

13. The method according to claim 1 wherein the step of determining that the starting cell population comprises a CD45 low cell sub-population and a CD45 high sub-population is performed using flow cytometry.

14. The method according to claim 1 wherein the relative increase in the number of CD45 low cells in the treated cell population, as compared the number of CD45 high cells in the treated cell population, is determined using flow cytometry.